Low-dose methotrexate plus steroid for early acute GVHD
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This Phase 3 trial tests whether a specific low-dose medication (methotrexate) together with standard steroid treatment can improve early outcomes in patients with acute graft-versus-host disease after a stem cell transplant. It may help control the immune reaction that attacks the body after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your guardian) can understand the study and sign consent
- This is your first allogeneic stem cell transplant (from a donor)
- You were diagnosed with acute graft-versus-host disease (grade II to IV) after the transplant
- Your general strength is good (KPS over 60) and doctors expect you to live more than 3 months
- Your blood counts and organ function are adequate (ANC > 0.5, creatinine < 1.5, and heart pumping looks acceptable)
- You are not pregnant or breastfeeding, and you have no uncontrollable active infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests whether adding leflunomide to standard steroid treatment can better control acute graft-versus-host disease (aGvHD) after a stem cell transplant. It may help reduce the immune reaction that damages the body while keeping treatment safe and manageable.
This trial tests a combination of a steroid and a humanized antibody (called CD25 monoclonal antibody) as the first treatment for moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if this combination is safer and more effective than steroids alone.
This study tests if a hormone called hCG can help treat moderate-to-severe graft-versus-host disease (GVHD) after a stem cell transplant. It is for adults who have recently developed GVHD and need steroids, but have not been on high-dose steroids for long.
This trial tests whether moxibustion—a traditional Chinese medicine technique using heat from burning mugwort—can help treat acute graft-versus-host disease (a complication after bone marrow transplant) that hasn't responded to steroid drugs. If you've had a stem cell transplant and developed this condition that won't go away with standard treatment, this study may be for you.
This trial tests new medications for people who develop severe acute graft-versus-host disease (aGVHD) within 100 days after their first stem cell transplant. The goal is to find safer, more effective ways to control aGVHD and improve recovery.
This trial tests a new combination of medicines to prevent graft-versus-host disease (GVHD) in patients with leukemia or myelodysplastic syndromes receiving a stem cell transplant from a half-matched donor. It aims to see if using less anti-thymocyte globulin (ATG) plus a simpler post-transplant cyclophosphamide (PTCy) regimen works as well as standard care with fewer side effects.
Hear when a new Acute Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.